APELLIS PHARMACEUTICALS INC. - COMMON STOCK

24,37

13-марта-25 15:45:00

15 мин. задержка

Акции

-0,81

-3,22%

Сегодняшний диапазон

24,27 - 25,28

ISIN

N/A

Источник

NASDAQ

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 сен 2024 15:05:00 Источник Nasdaq GlobeNewswire
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

29 авг 2024 06:00:00 Источник Nasdaq GlobeNewswire
Apellis and Sobi Announce Positive Topline Results from Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN

08 авг 2024 06:00:01 Источник Nasdaq GlobeNewswire
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 авг 2024 15:05:01 Источник Nasdaq GlobeNewswire
Apellis Pharmaceuticals Reports Second Quarter 2024 Financial Results

01 авг 2024 06:05:00 Источник Nasdaq GlobeNewswire
Apellis Pharmaceuticals to Host Conference Call on August 1, 2024, to Discuss Second Quarter 2024 Financial Results

18 июл 2024 06:00:00 Источник Nasdaq GlobeNewswire
Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting

09 июл 2024 06:00:00 Источник Nasdaq GlobeNewswire
Apellis Plans to Seek Re-Examination Following Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU

28 июн 2024 05:57:12 Источник Nasdaq GlobeNewswire
SYFOVRE® (pegcetacoplan injection) Preserved Visual Function at 36 Months in GALE Extension Study in Geographic Atrophy (GA)

10 июн 2024 06:00:00 Источник Nasdaq GlobeNewswire
Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference

05 июн 2024 06:00:00 Источник Nasdaq GlobeNewswire
Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress

24 май 2024 09:00:00 Источник Nasdaq GlobeNewswire
Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facility from Sixth Street

14 май 2024 07:00:00 Источник Nasdaq GlobeNewswire
Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results

07 май 2024 06:05:00 Источник Nasdaq GlobeNewswire
Apellis Pharmaceuticals to Host a Fireside Chat at the Bank of America Securities Healthcare Conference

06 май 2024 06:00:00 Источник Nasdaq GlobeNewswire
Apellis Announces 11 Oral Presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

01 май 2024 06:00:00 Источник Nasdaq GlobeNewswire
Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA)

26 апр 2024 06:15:00 Источник Nasdaq GlobeNewswire
Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial Results

23 апр 2024 06:00:14 Источник Nasdaq GlobeNewswire
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 апр 2024 15:05:00 Источник Nasdaq GlobeNewswire
Apellis Pharmaceuticals to Host a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

01 апр 2024 06:00:00 Источник Nasdaq GlobeNewswire
Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor

11 мар 2024 06:00:00 Источник Nasdaq GlobeNewswire

<<
<
1
2
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.